Maintaining Our Roche FVE Following Spark Deal; Fair Price to Expand Hemophilia Portfolio
Roche will acquire gene therapy firm Spark Therapeutics for $4.3 billion in a deal that not only adds to Roche's hemophilia portfolio but also gives access to gene therapy technology for use in other therapeutic areas, including ophthalmology, neurology, and other rare genetic diseases. Roche's tender offer of $114.50 in cash per share represents a 122% premium to Spark's closing price as of Feb. 22, and the deal is expected to close in the second quarter. Overall, we think Roche is paying a fai...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.